RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Budget-impact analysis of ibalizumab in the treatment of us Medicare beneficiaries with multidrug-resistant HIV-1 infection
La, E. M., Talbird, S. E., Brogan, A. J., & Davis, A. E. (2020). Budget-impact analysis of ibalizumab in the treatment of us Medicare beneficiaries with multidrug-resistant HIV-1 infection. Value in Health, 23, S174. Article PIN31. https://doi.org/10.1016/j.jval.2020.04.504
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.